These findings align with recent reports, including analyses of 684 endometrial carcinomas from TCGA and tumors from patients enrolled in the PORTEC-3 trial, which demonstrated that HER2 status lacks independent prognostic value after accounting for established clinicopathologic and molecular factors (Vermij, 2020). Here, ERBB2 is linked to endometrial carcinoma.